1.9392 USD
+0.09 (+4.82%)
Overall VTAK gets a fundamental rating of 2 out of 10. We evaluated VTAK against 188 industry peers in the Health Care Equipment & Supplies industry. VTAK may be in some trouble as it scores bad on both profitability and health. VTAK is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year VTAK has reported negative net income.
In the past year VTAK has reported a negative cash flow from operations.
VTAK had negative earnings in each of the past 5 years.
VTAK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VTAK has a Return On Assets of -94.12%. This is in the lower half of the industry: VTAK underperforms 78.72% of its industry peers.
VTAK has a Return On Equity of -354.30%. This is in the lower half of the industry: VTAK underperforms 77.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROIC | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTAK has a better Gross Margin (92.33%) than 98.40% of its industry peers.
VTAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTAK has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VTAK has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -18.10, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VTAK (-18.10) is worse than 86.17% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that VTAK is not too dependend on debt financing.
VTAK has a Debt to Equity ratio of 0.00. This is in the better half of the industry: VTAK outperforms 73.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.1 |
ROIC/WACCN/A
WACC7.17%
2.3 Liquidity
VTAK has a Current Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
VTAK has a worse Current ratio (0.44) than 94.15% of its industry peers.
A Quick Ratio of 0.43 indicates that VTAK may have some problems paying its short term obligations.
The Quick ratio of VTAK (0.43) is worse than 93.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.00% over the past year.
Looking at the last year, VTAK shows a very strong growth in Revenue. The Revenue has grown by 37.61%.
VTAK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 167.26% yearly.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
3.2 Future
Based on estimates for the next years, VTAK will show a very strong growth in Earnings Per Share. The EPS will grow by 40.75% on average per year.
VTAK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 312.31% yearly.
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VTAK's earnings are expected to grow with 40.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VTAK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:VTAK (11/25/2025, 10:43:16 AM)
1.9392
+0.09 (+4.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.76%
Inst Owner Change-99.99%
Ins Owners0.83%
Ins Owner Change0%
Market Cap2.89M
Revenue(TTM)600.00K
Net Income(TTM)-24.06M
Analysts85.71
Price Target38.76 (1898.76%)
Short Float %4.01%
Short Ratio0.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-59.17%
Min Revenue beat(2)-65.07%
Max Revenue beat(2)-53.27%
Revenue beat(4)0
Avg Revenue beat(4)-65.2%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-68.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-73.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-6.88
FCFYN/A
OCF(TTM)-6.87
OCFYN/A
SpS0.4
BVpS4.56
TBVpS-11.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% | ||
| FCFM | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.08% | ||
| Cap/Sales | 3.83% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | -18.1 |
F-Score5
WACC7.17%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A
CATHETER PRECISION INC / VTAK FAQ
What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VTAK.
What is the valuation status of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.
Can you provide the profitability details for CATHETER PRECISION INC?
CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.
How financially healthy is CATHETER PRECISION INC?
The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.
What is the earnings growth outlook for CATHETER PRECISION INC?
The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.